Sunnyvale, California-based DocSpera, a healthcare technology company, has completed a successful $10 million Series B financing round.
Surgical Coordination Platform DocSpera Raises $10M
1 min read Premium comments
Secondary#docspera
DocSpera’s platform is designed for intelligent surgical planning. The funds will be used to “accelerate commercialization of the existing suite of products (SmartSync™ and Intelligent Scheduler™ for Hospitals and ambulatory surgery centers (ASCs), and SmartEnterprise™ for Medtech and Life Science partners) as well as to invest in scaling the engineering, customer success and commercial teams to support their continued expansion.”
The financing round was led by Pier 70 Ventures, a venture capital firm based in Seattle, Washington, and JJDC, Inc. (Johnson & Johnson Innovation), a venture capital firm based in New Brunswick, New Jersey. Other investors participated as well.
Pier 70 Ventures Managing Partner Shaun Hawkins commented, “Pier 70 Ventures is excited to partner with DocSpera to help the company actualize its growth prospects. DocSpera provides unique and scalable technology solutions to efficiently address care collaboration and coordination challenges between healthcare providers and medical technology companies.”
Hawkins continued, “We were impressed with DocSpera’s vision and innovative technology. We have full confidence in the DocSpera team, the advisory board, and the company’s commercial plan.”
More than 300 health systems, provider practices, and ambulatory surgery centers utilize DocSpera to coordinate between medical device companies, care teams, and surgeons. The platform overcomes the obstacles providers face with communication and workflow via automation and streamlining information.
According to DocSpera, it’s solutions are compatible with more than 30 electronic medical records systems, picture archiving communication systems, and other key healthcare information technology systems. Additionally, the platform and solutions are Service Organization Control (SOC) 2 Type II certified.
DocSpera CEO Samuel Ethiopia said, “We are privileged to work with many of the leading surgical practices, health systems and medical device enterprises to drive operational efficiencies within the complex surgical and implant workflow, using our real-time and automated surgical workflow platform.”
Ethiopia continued, “Our experiences, recent market dynamics in the overall healthcare system, and constrained supply chains, reinforce the company’s value proposition across providers, suppliers, and ultimately patients.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.